Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.


BIO Report Finds Bioscience Drives Economic Growth in States Across U.S.

Washington, DC, September 20, 2017 — A report from Biotechnology Innovation Organization (BIO) unveiled in June concludes that the bioscience industry has had a positive impact on states’ economies and continues to be a driver of economic growth.

According to the new BIO report released in June, state lawmakers have recognized the importance of the industry, the authors state, and have responded to challenges facing the bioscience companies with legislative efforts focused on a supportive business climate. Continue reading

Life Sciences Talent Network Shaping Future Leaders in NJ’s Biotech Industry

Trenton, NJ, August 16, 2017Matt Alcalde, Director of Life Sciences Talent Network at BioNJ, writes:

Now in its second year, the Life Sciences Talent Advisory Board, managed by the Life Sciences Talent Network at BioNJ, has engaged over 100 employers from New Jersey’s robust health and life sciences industry.

These employers include pharmaceutical, biotechnology and medical device companies that are researching and developing new drugs and therapies to treat various diseases affecting patients worldwide as well as others who are supporting that work. Continue reading

NJ Economic Development Authority Board Takes Action to Drive Pharmaceutical Manufacturing Growth

Trenton, NJ, August 13, 2017 — The Board of the New Jersey Economic Development Authority (EDA) took action on August 8 that will help advance one of the key legislative objectives of the Economic Opportunity Act (EOA) — driving growth in targeted industries.

Potential investment in the manufacturing sector was highlighted at EDA Board meeting, as three manufacturers of pharmaceutical products were approved for Grow New Jersey (Grow NJ) tax credits to either locate or expand in New Jersey.

Grow NJ is the main job creation and retention program administered under the EOA. Continue reading

Opinion: Labor Leader Greg Lalevee on ‘Workers Win When Jersey Drug Companies Innovate’

Greg Lalevee

Springfield, NJ, June 21, 2017The Record/NorthJersey.com on June 15 published the following opinion piece by Greg Lalevee, Business Manager, the International Union of Operating Engineers Local 825:

New Jersey’s nickname, “Medicine Chest of the World,” is backed up by the numbers.

Our state is home to more than 3,000 life sciences establishments.  Thirteen of the world’s top 20 biopharmaceutical companies have made the Garden State their U.S. headquarters.

These firms are innovating and saving lives every day — and they couldn’t do it without help from supportive government policies and New Jersey’s well-trained and talented union workforce. Continue reading

PhRMA Report: Nearly 4.5 Million U.S. Jobs, $1.2 Trillion Economic Output Supported by Biopharmaceutical Sector in 2014

PhRMA jpgWashington, DC, May 18, 2016 ― The biopharmaceutical industry supported nearly 854,000 direct jobs and another 3.5 million jobs and more than $1.2 trillion in economic output in the United States in 2014, according to new research prepared for the Pharmaceutical Research and Manufacturers of America (PhRMA) by TEConomy Partners, LLC.

The report, which analyzed state and national data across the large-scale biopharmaceutical sector supply chain, highlights how the discovery, development and delivery of innovative medicines translate into higher-wage jobs, increased tax revenue and greater economic output in our local communities.

“The United States leads the world in bringing new medicines to market. Beyond the value that these medicines deliver to the patients who need them is the profound impact a strong biopharmaceutical sector has on our local, state and national economy,” said President and CEO of PhRMA Stephen J. Ubl. Continue reading

NJBIA Says Job Growth Stats Show NJ Economy Moving in Right Direction; New Job Training Centers Will Keep Economic Momentum Going

NJBIA Logo - CROPPEDTrenton, NJ, April 24, 2016 ― The New Jersey Business & Industry Association, representing 20,000 New Jersey businesses, hailed new government data released today indicating another round of solid monthly job gains in March, saying it showed the state’s economic recovery is sustained and accelerating.

The number of New Jersey residents reporting to have jobs reached a record high 4.37 million in March, according to the state Department of Labor & Workforce Development, citing preliminary data from the U.S. Bureau of Labor Statistics. Private-sector employers have added 265,000 jobs since February of 2010 at the height of the recession, the department said.

“The $2.3 billion in NJBIA-backed business tax cuts and reforms that have been enacted by the Governor and Legislature are allowing our businesses to make the investments they need for the future, and that is creating new jobs,” NJBIA President and CEO Michele Siekerka said. Continue reading

Rutgers Economic Advisory Service Reports NJ Economy Will Grow Slower than US’s Over Next 10 Years

New Brunswick, NJ, September 21, 2015The Record reported that New Jersey’s economy will continue to grow more slowly than the nation’s through 2025 before keeping pace with the national rate over the next 20 years, according to Nancy Mantell, director of the Rutgers Economic Advisory Service, at R/ECON’s semiannual subscriber conference Friday.

According to Rutgers, job growth in New Jersey will be 1.1 percent this year and next after recording a 0.7 percent gain in 2014, a decline of 17,400 jobs from 2013’s total. Continue reading

HINJ Op-Ed: Life Sciences Community Thriving in New Jersey’s ‘2.0 Business Environment’

New Brunswick, NJ,  December 1, 2014 ― The Asbury Park Press has published an op-ed by HINJ President and Chief Executive Officer Dean Paranicas regarding New Jersey’s “2.0 business environment” and its impact on the state’s life sciences community.

*     *     *

There have been reports that claim that New Jersey is no longer the pharmaceutical powerhouse it used to be, including a recent Asbury Park Press story by Michael L. Diamond (“What NJ Needs to Learn from Other States,” October 18, 2014).

We disagree.  To paraphrase Mark Twain, reports of New Jersey’s demise are greatly exaggerated.

For decades, New Jersey has rightly earned its reputation as the “Medicine Chest of the World” — and our state leaders are working with the life sciences industry to keep it that way. Continue reading

HINJ Responds to NPR Report on New Jersey’s Biopharma Sector

New Brunswick, NJ, July 31, 2014 The HealthCare Institute of New Jersey (HINJ) has responded as follows to a National Public Radio (NPR) report regarding New Jersey’s biopharmaceutical sector.

*     *     *

Dan Tucker’s story opens by stating that New Jersey “used to be known as ‘the nation’s medicine chest.’”  While the HealthCare Institute of New Jersey (HINJ) acknowledges that there are a number of vacant pharmaceutical facilities in the state, the status of industry real estate alone is not a true barometer of the industry’s strength in New Jersey.

HINJ contends that — with 13 of the world’s top 20 biopharmaceutical companies and 12 of the world’s top 20 medical technology companies maintaining a significant presence in New Jersey, with the state being one of the largest life sciences clusters in the U.S., and with recent expansion and relocation activity in the state — the Garden State remains the “medicine chest of the world.”

In contrast, this story leads the audience to infer a rather bleak picture and outlook for New Jersey’s life sciences community.

In fact, there are a number of signs that point to an energized life sciences community in New Jersey that were not reflected in this story. Continue reading

HINJ Releases 2013 Economic Impact Report and ‘HINJ and NJ’s Life Sciences Community’ Brochure

New Brunswick, NJ, May 13, 2014 — The HealthCare Institute of New Jersey (HINJ) has released two new publications:  the 2013 Economic Impact Report and a new external (leave-behind) brochure entitled HINJ and New Jersey’s Life Sciences Community.

Printed copies of each publication are being mailed to HINJ member companies and to our many stakeholders, including members of New Jersey’s Congressional Delegation, Governor Christie and his administration and the State Legislature. Continue reading